Reply to Francesco Montorsi, Giorgio Gandaglia, Francesco Barletta, and Alberto Briganti’s Letter to the Editor re: Bertrand F. Tombal, Francisco Gomez-Veiga, Alvaro Gomez-Ferrer, et al. A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532). Eur Urol Oncol 2024;7:1051–60

Tombal, Bertrand; Loriot, Yohann

doi:10.1016/j.euo.2025.01.010

Reply to Francesco Montorsi, Giorgio Gandaglia, Francesco Barletta, and Alberto Briganti’s Letter to the Editor re: Bertrand F. Tombal, Francisco Gomez-Veiga, Alvaro Gomez-Ferrer, et al. A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532). Eur Urol Oncol 2024;7:1051–60

Tombal, Bertrand

;

Loriot, Yohann

(2025) European Urology Oncology — Vol. 8, n° 3, p. 853 (2025)

Files

No attached file found for this publication.

Details

Authors

Tombal, BertrandUCLouvain
Author
Loriot, Yohann
Author

Affiliations

UCLouvainSSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation

Citations

APA
Chicago
FWB

Tombal, B., & Loriot, Y. (2025). Reply to Francesco Montorsi, Giorgio Gandaglia, Francesco Barletta, and Alberto Briganti’s Letter to the Editor re: Bertrand F. Tombal, Francisco Gomez-Veiga, Alvaro Gomez-Ferrer, et al. A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532). Eur Urol Oncol 2024;7:1051–60. European Urology Oncology, 8(3), 853. https://doi.org/10.1016/j.euo.2025.01.010 (Original work published 2025)